By demonstrating the effectiveness of JAK2 and STAT3 inhibitors in preclinical models, our findings support their potential as therapeutic strategies to counteract mutp53-induced tumor aggressiveness and immunosuppression, paving the way for targeted therapies that could significantly improve outcomes in CRPC treatment. This evidence concerns the gene JAK2 and neoplasm.